Voglio sapere a riguardo di…

54552

Federal Register / Vol. 86, No. 188 / Friday, October 1, 2021 / Notices
to the Respondents pharmacy, an additional 45.4 miles to A.R.s home, for a total of 97.3 miles round-trip to fill the oxycodone prescriptions.
Patient A.V.
From April 12, 2016, to at least April 10, 2017, the Respondent filled at least 9 prescriptions for buprenorphine and at least 12 prescriptions for oxycodone for A.V. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
a. A.V.s prescriptions were for 112
tablets of oxycodone 20 mg and 60
tablets buprenorphine 8 mg, which are large amounts of tablets at a high dosage strength.
b. A.V. was filling prescriptions for opioid withdrawal at the same time he was filling a prescription for an opioid.
c. A.V. filled his prescriptions for short acting oxycodone since at least April 12, 2016, even though oxycodone was not prescribed for long-term use or chronic conditions.
Patient B.F.
From October 27, 2015, to at least May 15, 2017, the Respondent filled at least 17 prescriptions for hydromorphone and at least 5
prescriptions for oxycodone for B.F.
outside the usual course of professional practice, in violation of 21 CFR 1306.06, and in violation of its corresponding responsibility under 21 CFR 1306.04a.
Specifically:
a. B.F.s prescriptions were for 84
tablets of hydromorphone 8 mg, which is a large amount of tablets at the highest dosage strength.
b. B.F. filled his prescriptions for short acting hydromorphone since at least October 27, 2015, even though hydromorphone is not prescribed for long-term use or chronic conditions.
c. B.F. paid cash for his prescriptions at inflated prices, paying $490.00 for 84
tablets of hydromorphone 8 mg, approximately $5.93 per pill, at a time when legitimate pharmacies were charging approximately $1.50.
Patient B.N.
From January 22, 2016, to at least June 2, 2017, the Respondent filled at least 9
prescriptions for hydromorphone and at least 10 prescriptions for oxycodone for B.N. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
a. B.N.s prescriptions were for 100
tablets of hydromorphone 8 mg, which is a large amount of tablets at the
VerDate Sep<11>2014

20:19 Sep 30, 2021

Jkt 256001

highest dosage strength. In September 2016, B.N. switched to 120 tablets of oxycodone 30 mg, which is an even higher number of tablets at the highest dosage strength of oxycodone.
b. B.N. filled his prescriptions for immediate release oxycodone and hydromorphone since at least January 22, 2016, even though oxycodone and hydromorphone are not prescribed for long-term use or chronic conditions.
c. B.N. paid cash for his prescriptions at inflated prices, paying up to $640.00
for 100 tablets of hydromorphone 8 mg, approximately $6.40 per pill, at a time when legitimate pharmacies were charging approximately $1.50.
Similarly, B.N. paid prices up to $650.00 for 120 tablets of oxycodone 30
mg, approximately $5.51 per pill, at a time when legitimate pharmacies were charging approximately $0.90 per tablet.
Patient K.Y.D.5
From February 4, 2016, to at least June 12, 2017, the Respondent filled at least 17 prescriptions for oxycodone and at least 17 prescriptions for morphine sulfate for K.Y.D. outside the usual course of professional practice, in violation of 21 CFR 1306.06, and in violation of its corresponding responsibility under 21 CFR 1306.04a.
Specifically:
a. K.Y.D.s prescriptions for hydromorphone were for 84 tablets of oxycodone 30 mg, which is a large amount of tablets at the highest dosage strength.
b. K.Y.D. paid cash for his prescriptions at inflated prices, paying up to $290.00 for 84 tablets of oxycodone 30 mg, approximately $3.45
per tablet, at a time when legitimate pharmacies were charging approximately $0.90 per tablet.
Patient K.E.D.
From October 26, 2015, to at least June 7, 2017, the Respondent filled at least 20 prescriptions for oxycodone for K.E.D. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
5 There are two patients with the same initials, K.D. In pretrial filings, the Government and Respondent referred to these patients as K.D.1 and K.D.2. However, the Government and Respondent referred to different patients as K.D.1 and K.D.2
i.e., the Governments K.D.1 was Respondents K.D.2. At the hearing, the parties discussed this issue and decided to refer to these two patients by the first two letters in their first name. All of the Governments pre-trial filings referring to K.D.1 are now discussed as K.Y.D. All of the Governments pre-trial findings referring to K.D.2 are now discussed as K.E.D. The opposite is true for the Respondent.

PO 00000

Frm 00004

Fmt 4701

Sfmt 4703

a. K.E.D.s prescriptions for oxycodone were for 112 tablets of oxycodone 20 mg, which is a large amount of tablets at a high dosage strength.
b. K.E.D. filled his prescriptions for immediate release oxycodone since at least October 26, 2015, even though oxycodone is not prescribed for longterm use or chronic conditions.
c. K.E.D. paid cash for his prescriptions at inflated prices, paying up to $430.00 for 112 tablets of oxycodone, approximately $3.83 per tablet, at a time when legitimate pharmacies were charging approximately $0.90 per tablet.
Patient R.R.
From October 28, 2015, to at least May 30, 2017, the Respondent filled at least 21 prescriptions for oxycodone for R.R. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
a. R.R.s prescriptions for oxycodone were for 112 tablets of oxycodone 15
mg, which is a large amount of tablets at a high dosage strength.
b. R.R. filled his prescriptions for immediate release oxycodone since at least October 28, 2015, even though oxycodone is not prescribed for longterm use or chronic conditions.
Patient R.V.
From November 17, 2015, to at least June 19, 2017, the Respondent filled at least 21 prescriptions for oxycodone for R.V. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
a. R.V.s prescriptions for oxycodone were for 112 to 120 tablets of oxycodone 20 mg, which is a large amount of tablets at a high dosage strength.
b. R.V. filled her prescriptions for immediate release oxycodone since at least November 17, 2015, even though oxycodone is not prescribed for longterm use or chronic conditions.
Patient V.W.
From November 30, 2015, to at least May 31, 2017, the Respondent filled at least 20 prescriptions for oxycodone for V.W. outside the usual course of professional practice, in violation of 21
CFR 1306.06, and in violation of its corresponding responsibility under 21
CFR 1306.04a. Specifically:
a. V.W.s prescriptions for oxycodone were for 84 to 112 tablets of oxycodone 15 mg, which is a large amount of tablets at a high dosage strength.

E:FRFM01OCN2.SGM

01OCN2